OPT Opthea Ltd. Total Debt to Capital

The asset value tracked on this chart demonstrates a total debt-to-equity ratio of 0.00. Opthea Limited (OPT) relies on cross-border cold-chain delivery of biologics, mitigating supply risks through its warehouse network. The company is developing a unique treatment for macular degeneration that blocks VEGF-C/D proteins. Meanwhile, the expansion of clinical trials requires massive expenditures, temporarily increasing unit costs pending the FDA verdict.

OPT Opthea All Debt to Shareholders' Equity Ratio (07/04/2022 - 06/28/2025)

Analytical breakdowns for Opthea Limited

- price and consensus price forecast:

Stock Price Opthea|OPT - Fair Value Consensus

- market capitalization data:

Market Capitalization Opthea|OPT - Enterprise Value

- book capitalization data:

Net Assets per Single Share Opthea|OPT - Accounting Value of Company|Market Value to Book Value Ratio opthea.com|OPT - Cumulative Company Assets

- debt and liquidity data:

Total Debt to Capital Opthea Limited|OPT - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio Opthea Limited|OPT - Aggregate Debt Obligations|Debts to Book Capitalization Opthea

Basic company analysis:Opthea OPT

This ratio is calculated as the proportion of total debt to equity, determining the business's degree of dependence on external financing and its overall solvency. For Opthea Limited (OPT), which utilizes contract manufacturing facilities, a low debt-to-equity ratio confirms the absence of capital-intensive production costs, thereby minimizing credit risks during the development of new molecules.

Analysis of competing companies